Further maintenance of remission for a year after infliximab withdrawal in ulcerative colitis treatment: a multicenter, controlled trial in Japan
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2019
Price : $35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms HAYABUSA
- 22 Apr 2019 Status changed from recruiting to completed.
- 05 Mar 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan.
- 08 Dec 2013 New trial record